Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus erythematosus (SLE) have been revealed, and have not disappointed.
Many of our academics speak to the media as experts in their field of research. If you are a journalist, please contact the University’s Media and PR Team: Catalysis offers the prospect of low energy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback